Downloading...
Download

Optionstrader

GE Aerospace Options Ahead of EarningsIf you haven`t bought GE before the rally: Now analyzing the options chain and the chart patterns of GE Aerospace prior to the earnings report this week, I would consider purchasing the 270usd strike price Calls with an expiration date of 2025-8-15, for a premium of approximately $8.60. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:GELong
by TopgOptions
ASML Holding Options Ahead of EarningsIf you haven`t bought the dip on ASML: Now analyzing the options chain and the chart patterns of ASML Holding prior to the earnings report this week, I would consider purchasing the 800usd strike price Calls with an expiration date of 2025-7-25, for a premium of approximately $32.00. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:ASMLLong
by TopgOptions
Carvana Leading Auto Retail – Outpacing LAD & AN-Financial Performance & Momentum: Carvana reported a record-breaking adjusted EBITDA of $488M in Q1 2025, up $253M YoY, with an EBITDA margin of 11.5% (+3.8pp YoY). The company's strong operational efficiency positions it as a leader in the auto retail industry, nearly doubling the margins of competitors like Lithia Motors (LAD) and AutoNation (AN). - Competitive Positioning & Growth Outlook: Carvana’s EBITDA quality is superior due to lower non-cash expenses, enhancing long-term sustainability. The company expects sequential EBITDA growth in Q2 and targets 13.5% EBITDA margins within 5-10 years. -Peer Comparison: - Lithia Motors (LAD): EBITDA margin at 4.4% (up from 4% YoY), facing tariff-related headwinds that could impact pricing and demand. - AutoNation (AN): SG&A as a percentage of gross profit rose to 67.5% in Q1, expected to stay between 66-67% in FY 2025, pressuring margins further. -Options Flow & Institutional Activity - Key Levels: $350/$370 Recent institutional flow activity indicates strong positioning around $350/$370 strikes, potentially signaling a vertical spread in play rather than outright selling: 1️⃣ Momentum Confirmation: - CVNA has strong upside momentum following its Q1 results, reinforcing a bullish outlook for near-term price action. - Institutional traders may be accumulating bullish vertical spreads rather than unwinding positions. Vertical Spread Setup ($350/$370 Strikes) - Long Call ($350 Strike) → Signals expectations for further upside. - Short Call ($370 Strike) → Caps max profit while reducing cost. - Breakeven Price: $359 → CVNA must close above $359 for profitability. Profit & Risk Zones - Above $370: Maximum profit achieved. - Between $359-$370: Partial profit zone (spread remains in play). - Below $359: Spread loses value, making recovery dependent on extended upside momentum.
NYSE:CVNALong
by Wiiso
Why IonQ (IONQ) Could Be the NVDA of Quantum ComputingIf you haven`t bought IONQ before the rally: Now you need to know that IonQ isn’t just another speculative quantum stock — The company is building a robust ecosystem around its best‑in‑class trapped‑ion architecture and targeting fault‑tolerant, networked quantum systems. With record bookings, major acquisitions, and a strong balance sheet, IonQ could emerge as the NVIDIA equivalent for quantum infrastructure. Key Bullish Arguments 1) Superior Quantum Tech – Trapped‑Ion Advantage IonQ’s trapped-ion processors boast 99.9% two-qubit fidelity, demonstrating higher accuracy and scalability than superconducting alternatives These systems also operate at room temperature, meaning simpler deployment and lower costs 2) Ecosystem Strategy & Acquisitions The $1.08B acquisition of Oxford Ionics (expected close in 2025) expands IonQ’s qubit control tech, pushing toward planned 80,000 logical‑qubit systems by decade’s end Combined with ID Quantique and Lightsynq, IonQ is building a full-stack quantum and networking offering 3) Strong Revenue Growth & Cash Runway Revenue soared from $22M in 2023 to $43.1M in 2024, with bookings of $95.6M . Q1 2025 saw $7.6M revenue and EPS –$0.14, beating expectations; cash reserves near $697M provide years of runway 4) Real Commercial Deployments IonQ sold its Forte Enterprise quantum system to EPB ($22M deal) for hybrid compute and networking, marking real-world commercial applications 5) AI & Quantum Synergy Involvement in NVIDIA’s Quantum Day and hybrid quantum‑classical AI demos (e.g., blood pump simulation with Ansys, ~12 % faster) indicates strategic synergy and positions IonQ as a critical piece in the future AI stack Recent Catalysts: Texas Quantum Initiative passes – positions IonQ at forefront of U.S. state-backed innovation Oxford Ionics acquisition pending – major expansion in qubit scale & tech Barron’s analyst buys – industry analysts see long-term potential; IonQ among top quantum picks Broader quantum optimism – McKinsey & Morgan Stanley forecasts highlight synergy between quantum and AI, benefiting IonQ
NYSE:IONQLong
by TopgOptions
AAPL: Premium PlayApple beat expectations this quarter—revenue, profit, EPS—all slightly better than analysts hoped. But the stock dropped to $196.26, down from $212.83. Why? Investors are still worried about tariffs, margin pressure, and supply chain changes. Tim Cook talked about strong product sales (iPhone, Mac, iPad) and all-time high Services revenue. But he also admitted tariffs and regulatory issues are weighing on Apple’s outlook. My Covered Call Strategy I’m selling the $202.5 call and buying the $210 call for June 27, 2025. Big money seems to be doing the same—there was a huge premium sale over $2 million, likely betting Apple stays range-bound short term. - Why this works: - Resistance near $202.50 gives me a clear ceiling - Apple fundamentals are strong, but macro risk caps upside Chart Notes - Resistance: $202.50 and $210 - Support: Around $192.50 Bottom line: I like this trade as a way to bring in income while defining my risk. If Apple grinds sideways or pushes a bit higher, the trade still pays. Clean structure, high odds.
NASDAQ:AAPL
by Wiiso
Jade Lizard on PLTR - My 53DTE Summer Theta PlayMany of you — and yes, I see you in my DMs 😄 — are trading PLTR, whether using LEAPS, wheeling, or covered calls. I took a closer look. And guess what? 📈 After a strong move higher, PLTR was rejected right at the $143 call wall — pretty much all cumulative expiries cluster resistance there Using the GEX Profile indicator, scanning all expirations: After a brief dip, the market is repositioning bullish Squeeze zone extends up to 150 The most distant GEX level is sitting at 160 On the downside, 130 is firm support, with some presence even at 120 — the market isn’t pricing in much risk below that 📉 From a technical standpoint: We’re near all-time highs 125 (previous ATH) and 100 are key support levels The OTM delta curve through August is wide, and the call side is paying well — with a current call pricing skew 🔬 IVx is at 57, trending lower + call pricing skew📉 IV Rank isn't particularly high, but the directional IVx matters more here 💡 Summer Theta Play: Jade Lizard on PLTR Since I’ll be traveling this summer and don’t want to micromanage trades, I looked for something low-touch and high-confidence — and revisited an old favorite: the Jade Lizard. If you're not familiar with the strategy, I recommend checking out Tastytrade's links and videos on Jade Lizards. 🔹 Why this setup? Breakeven sits near $100, even with no management On TastyTrade margin:~$1800 initial margin ~$830 max profit 53 DTE — plenty of time for theta to work Earnings hit in August — I plan to close before then Covers all bullish GEX resistance zones Quickly turns profitable if IV doesn’t spike Highly adjustable if needed My conclusion: this strategy covers a much broader range than what the current GEX Profile shows across all expirations — so by my standards, I consider this to be a relatively lower-risk setup compared to most other symbols right now with similar theta strategies. 🔧 How would I adjust if needed? If price moves up: I’d roll the short put up to collect additional credit Hold the call vertical as long as the curve supports it If price drops: Transition into a put ratio spread Either extend or remove the call vertical depending on conditions 🛑 What’s the cut loss plan? I have about 20% wiggle room on the upside, so I’m not too worried — but if price rips through 160 quickly, I’ll have to consider early closure. If that happens, the decision depends on time: If late in the cycle with low DTE:→ Take a small loss & roll out to next month for credit If early with lots of DTE remaining:→ Consider converting to a butterfly, pushing out the call vertical for a small debit→ Offset this with credit from rolling the put upward As always — stay sharp, manage your risk, and may the profit be with you. See you next week!– Greg @ TanukiTrade
NASDAQ:PLTR
by TanukiTrade
2
MU Micron Technology Options Ahead of EarningsIf you haven`t bought MU before the rally: Now analyzing the options chain and the chart patterns of MU Micron Technology prior to the earnings report this week, I would consider purchasing the 128usd strike price Calls with an expiration date of 2025-6-27, for a premium of approximately $5.52. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:MULong
by TopgOptions
MKC McCormick & Company Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MKC McCormick & Company prior to the earnings report this week, I would consider purchasing the 85usd strike price Calls with an expiration date of 2026-1-16, for a premium of approximately $1.40. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:MKCLong
by TopgOptions
MU Options Insight: Bulls Eyeing $123Fundamental Overview Micron Technology's $200 billion expansion plan aligns with the broader push for domestic semiconductor manufacturing. The company is investing $150 billion in fabrication plants across Idaho, New York, and Virginia, while $50 billion is allocated for high-bandwidth memory packaging and R&D. This move strengthens Micron’s position in AI-driven demand and supply chain resilience. The CHIPS and Science Act funding of $6.4 billion and eligibility for the Advanced Manufacturing Investment Credit further bolster Micron’s financial outlook. CEO Sanjay Mehrotra emphasized that this expansion will create tens of thousands of jobs and reinforce U.S. tech leadership. Technical Analysis Micron’s stock is currently near a 12-month high, up 37% year to date. The momentum remains strong, with institutional activity suggesting bullish sentiment. - Options Flow Insight: A vertical bull spread was spotted in Times & Sales, with 118 strike contracts executed on the ask and 123 strike contracts executed on the bid simultaneously. This suggests a bullish stance, as traders anticipate further upside. - Expiration Consideration: The June 20 expiration (4 days away) indicates a short-term bullish outlook, likely targeting a breakout above $123. - Institutional Positioning: The 500 additional contracts at 118 reinforce the bullish bias. If MU moves beyond $123, traders holding the spread still profit, confirming strong conviction in upside potential.
NASDAQ:MULong
by Wiiso
Why Recursion Pharmaceuticals RXRX Could Be the NVDA of BiotechRecursion Pharmaceuticals RXRX is rapidly emerging as a transformative force in drug discovery, leveraging cutting-edge artificial intelligence and automation to industrialize and accelerate the development of new medicines. Here’s why RXRX could be the next NVIDIA (NVDA) of biotechnology and why its stock could soar by year-end: 1. AI-Powered Drug Discovery Platform with Unmatched Scale Recursion integrates AI, machine learning, automation, and advanced data science to decode biology and chemistry, dramatically reducing the time and cost of drug discovery. The company’s proprietary BioHive-2 supercomputer, built with NVIDIA’s DGX H100 systems, is the most powerful AI computing system wholly owned by any biopharma company, enabling Recursion to process biological data at unprecedented speeds. By reducing the number of compounds needed for clinical candidates from thousands to just 136–200 and shrinking development timelines to under a year, RXRX is fundamentally changing the economics of pharmaceutical R&D. 2. Strategic Partnerships and Industry Validation RXRX has forged high-profile partnerships with pharmaceutical giants such as Bayer, Roche/Genentech, Takeda, and Sanofi, validating its platform and unlocking milestone payments that could exceed $20 billion over time. The company’s collaboration with AI biotech Exscientia in a $700 million deal further cements its leadership in the AI-driven drug discovery space, creating a pipeline of 10 clinical and preclinical programs with hundreds of millions in potential milestones. NVIDIA itself holds over 7.7 million shares of RXRX, making it one of NVIDIA’s largest biotech investments and a strong endorsement of Recursion’s technology and long-term vision. 3. Explosive Revenue Growth and Strong Cash Position Analysts forecast Recursion’s revenue to grow at a 65% CAGR from $58.8 million in 2024 to $263 million by 2027, far outpacing the broader biotech sector. The company ended 2024 with over $600 million in cash, providing a solid runway for continued investment in R&D, platform expansion, and clinical trials. Wall Street analysts expect more than 50% upside in RXRX stock over the next 12–24 months, with multiple clinical milestones and partnership announcements as near-term catalysts. 4. Disruptive Vision: The “Virtual Cell” and Beyond RXRX is building toward a “virtual cell,” where AI models can simulate biological processes with such accuracy that wet lab experiments shift from data generation to validating computational predictions. This approach could dramatically improve drug development success rates, addressing the industry’s notorious 95% failure rate and positioning Recursion as the go-to platform for next-generation drug discovery. 5. Market Sentiment and Institutional Support RXRX has caught the attention of growth investors and major funds, including Cathie Wood’s ARK Invest, further boosting its profile and liquidity. Recent stock surges and high trading volumes reflect growing investor confidence in Recursion’s disruptive potential and the broader AI-in-biotech trend.
NASDAQ:RXRXLong
by TopgOptions
11
NVDA GEX Earnings Outlook by OptionsNVDA reports earnings this Wednesday, and it’s a big deal. A major move could impact both the indexes and broader tech sector. The OTM 16 delta curve essentially overlaps with both the GEX profile and the expected probability zone — signaling strong confluence. 📈 Rising IV with falling call skew: Volatility is rising into earnings, while the call skew is dropping — a sign of growing interest in downside hedging/speculation. 🔷 Key inflection zone (129): Above 129, the market is unlikely to surprise. Below it, however, a domino effect could trigger increased volatility and put-side flows. Implied move into earnings is 6.62%, reflecting binary risk expectations from the options market. Strong gamma squeeze territory exists between 140–145, with significant call wall buildup around 140. The nearest expiry shows a positive net GEX — supporting short-term mean-reversion or hedging flow stability above 129, at least until the earnings print. 🔴 Downside risk scenario: In the event of a downward move, the market is most heavily hedged around the 125 level, which aligns with the deepest put support. 💡 Wheeling Opportunity Idea ONLY IF you want to own NVDA long-term around the $130 level (even if it drops short/mid-term), this might be a great time to start the wheeling strategy. Because earnings inflate volatility, you can sell a near-term cash-secured put (CSP) for solid premium — even on a 53DTE (July) option. Based on current GEX levels, we’re seeing: -Support (squeeze zone) around $125 -Call resistance around $140 -A potential upside squeeze extending to $145-$150 These align roughly with ~20 delta OTM options, so the premium is attractive. How would I personally start this: Sell a CSP for May 30 with the intention to get assigned if NVDA drops. If I do get assigned, I’m happy to own shares. Then, I sell a 60DTE covered call right after to collect another round of premium. If I’m not assigned, I sell a new 45–60DTE put the following week — still benefiting from the relatively high IV. 👉 Remember: High IV = synthetic time value. With this two-step method, you can harvest premium twice in quick succession. I used the same technique with NASDAQ:INTC , and it’s been performing well. 💥 ONLY IF you want to own NVDA long-term around the $130 level (even if it drops short/mid-term)!
NASDAQ:NVDA
by TanukiTrade
ZS Zscaler Options Ahead of EarningsIf you haven`t bought the dip on ZS: Now analyzing the options chain and the chart patterns of ZS Zscaler prior to the earnings report this week, I would consider purchasing the 250usd strike price Puts with an expiration date of 2026-1-16, for a premium of approximately $29.30. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:ZSShort
by TopgOptions
AMZN Amazon Options Ahead of EarningsIf you haven`t bought AMZN before the previous rally: Now analyzing the options chain and the chart patterns of AMZN Amazon prior to the earnings report this week, I would consider purchasing the 210usd strike price Calls with an expiration date of 2025-6-20, for a premium of approximately $3.75. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Disclosure: I am part of Trade Nation's Influencer program and receive a monthly fee for using their TradingView charts in my analysis.
TRADENATION:AMZNLong
by TopgOptions
GEX Analysis & Options “Game Plan”🔶 Short- and longer-term perspective in a high IV, negative GEX environment 🔶 KEY LEVELS & RANGES Spot: 221 Gamma Flip / Transition: around 250 (the turquoise zone on the chart) – This zone typically marks a “power shift.” If price decisively breaks above 250 and holds, market makers’ gamma positioning could flip from neutral/negative to positive. Put Support: 200 – A large negative gamma position has accumulated here, making 200 a strong support level. If it breaks, the downside may accelerate. Call Resistance: 400 – A major long-term “call wall” where a significant amount of OTM calls are concentrated. It’s more relevant to LEAPS; currently far from spot, so not a realistic short-term target. Call Resistance #2: 300 – A medium-term bullish objective, still above the 200-day MA. You’d need to be strongly bullish to aim for ~300 by May (e.g., going for a 16-delta OTM call). Short-Term / Intermediate GEX Levels: – There are gamma clusters around 220–230 and 250–260 . These areas often see higher volatility, possible bounces, or stalls (chop) due to hedging flows. 🔶 WHATEVER SCENARIO – SHORT TERM (0–30 DAYS) A) Upside Continuation / Rebound – If TSLA closes above 225–230 , the next target is 240–250 (transition / gamma flip). – If it breaks above 250 and holds (e.g., successful retest), market makers may shift to “long gamma,” fueling a quicker move to 260–270 . – Resistance: 250, 300, with an extreme LEAPS-level at 400. B) Downside Move / Bearish Break – If price dips below ~220 and sustains, the next targets are 210–200 (major put wall / negative gamma). – If 200 fails, negative gamma may magnify the sell-off. It’s an extreme scenario but still on the table given high IV and macro/geopolitical risks. – Support: 210, 200 — likely stronger buying interest near 200, possibly a short-term bounce. – The options chain suggests near-term hedging via puts for this scenario. C) Chop / Sideways – If TSLA stays in 210–230 , market makers (short options) might benefit from high IV/time decay. – Negative GEX, however, can trigger sudden moves in either direction; caution is advised. 🔶 LONGER-TERM FOCUS (6–12 MONTHS, LEAPS) NET GEX = -61.97M (negative territory) suggests longer-dated positioning is also put-heavy or carries notable negative gamma. HVL / pTrans = 250 is a key pivot; cTrans+ = 400 is distant call resistance. Between these levels, there’s a mix of put/call dominance. If Tesla undergoes a fresh growth phase (AI, robotaxi, energy storage, etc.) and clears 250/300 , 400 could become the next significant call wall — but that’s more of a multi-month horizon. 🔶 STRATEGY IDEAS (High IV Environment) 1. Short-Term Bearish – If you’re bearish and expecting TSLA to test 220–210, consider a bear put spread or net credit put butterfly (lower debit) to leverage high IV. – Targeting 200, but keep in mind negative gamma may accelerate downside movement. 2. Medium-Term “Contra” Bullish (bounce to 250) – If GEX suggests a bounce off 210–220, consider a bull call spread (e.g., 220/240) or a net debit call butterfly (220/240/250). – Be mindful of sudden swings, as we remain in negative gamma territory. 3. Longer-Term Bullish (>3–6 months) – A call butterfly with upper strikes around 300–350 offers capped debit and higher potential payoff if a bigger rally materializes. – A diagonal spread (selling nearer-dated calls, buying further-out calls) exploits elevated front-end IV. 4. Neutral / Range-Bound – If TSLA stays in 200–250 , you could use Iron Condors (e.g., 200/260) to benefit from time decay and any IV collapse. – Exercise caution: negative gamma can generate abrupt, directional moves, making a neutral stance riskier than usual. 🔶 ADDITIONAL NOTES & “BIG PICTURE” High IV & Negative GEX: TSLA has a track record of large swings. Negative GEX can intensify sell-offs, while forced hedging might trigger rapid rebounds. Preferred Structures: With expensive premiums, spreads (vertical, diagonal) and butterfly configurations generally fare better than plain long options (less vulnerable to time decay). Potential Catalysts: AI announcements, Autopilot breakthroughs, new product lines, and macro changes can swiftly alter market dynamics. Keep tracking GEX updates and news flow; TSLA tends to respond dramatically to fresh developments. 🔶 Bottom line: From 221 spot, watch 210–200 on the downside and 240–250 on the upside short term. Medium-term bullish target = 300 , while 400 remains a far LEAPS scenario. High IV + negative gamma = fast, potentially volatile moves — so risk management and spread-based approaches are crucial.
NASDAQ:TSLA
by TanukiTrade
1